Valproic Acid Synergizes With Cisplatin and Cetuximab in vitro and in vivo in Head and Neck Cancer by Targeting the Mechanisms of Resistance-Reference-Cited by-同舟云学术

Valproic Acid Synergizes With Cisplatin and Cetuximab in vitro and in vivo in Head and Neck Cancer by Targeting the Mechanisms of Resistance

Published:2020-08-17 Issue: Volume:8 Page:
ISSN:2296-634X
Container-title:Frontiers in Cell and Developmental Biology
language:
Short-container-title:Front. Cell Dev. Biol.

Author:

Iannelli Federica,Zotti Andrea Ilaria,Roca Maria Serena,Grumetti Laura,Lombardi Rita,Moccia Tania,Vitagliano Carlo,Milone Maria Rita,Ciardiello Chiara,Bruzzese Francesca,Leone Alessandra,Cavalcanti Ernesta,De Cecio Rossella,Iachetta Giuseppina,Valiante Salvatore,Ionna Franco,Caponigro Francesco,Di Gennaro Elena,Budillon Alfredo

Funder

Ministero della Salute

Regione Campania

Associazione Italiana per la Ricerca sul Cancro

Publisher

Frontiers Media SA

Subject

Cell Biology,Developmental Biology

Reference59 articles.

1. DNA damage response and resistance of cancer stem cells.;Abad;Cancer Lett.,2020

2. A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer.;Arce;PLoS One,2006

3. Phase 1/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperative treatment in low-moderate risk rectal cancer-V-shoRT-R3 (Valproic acid–short Radiotherapy–rectum 3rd trial).;Avallone;BMC Cancer,2014